Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Retained Earnings (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Retained Earnings for 8 consecutive years, with -$20000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings changed N/A to -$20000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$20000.0 for FY2025, N/A changed from the prior year.
  • Retained Earnings for Q4 2025 was -$20000.0 at Actinium Pharmaceuticals, up from -$403.8 million in the prior quarter.
  • The five-year high for Retained Earnings was -$20000.0 in Q4 2025, with the low at -$403.8 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$296.1 million, with a median of -$299.8 million recorded in 2023.
  • The sharpest move saw Retained Earnings dropped 18.03% in 2023, then fell 9.37% in 2025.
  • Over 5 years, Retained Earnings stood at -$255.7 million in 2021, then fell by 12.91% to -$288.8 million in 2022, then decreased by 16.91% to -$337.6 million in 2023, then dropped by 9.36% to -$369.2 million in 2024, then surged by 99.99% to -$20000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$20000.0, -$403.8 million, and -$398.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.